Abstract
Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in England starting on 14 September 2021. We used a test-negative case-control design to estimate the relative effectiveness of a booster dose of BNT162b2 (Pfizer-BioNTech) compared to only a two-dose primary course (at least 175 days after the second dose) or unvaccinated individuals from 13 September 2021 to 5 December 2021, when Delta variant was dominant in circulation. Outcomes were symptomatic coronavirus disease 2019 (COVID-19) and hospitalization. The relative effectiveness against symptomatic disease 14-34 days after a BNT162b2 or mRNA-1273 (Moderna) booster after a ChAdOx1-S (AstraZeneca) and BNT162b2 as a primary course ranged from around 85% to 95%. Absolute vaccine effectiveness ranged from 94% to 97% and was similar in all age groups. Limited waning was seen 10 or more weeks after the booster. Against hospitalization or death, absolute effectiveness of a BNT162b2 booster ranged from around 97% to 99% in all age groups irrespective of the primary course, with no evidence of waning up to 10 weeks. This study provides real-world evidence of substantially increased protection from the booster vaccine dose against mild and severe disease irrespective of the primary course.
【초록키워드】 COVID-19, coronavirus disease, Coronavirus disease 2019, Vaccine, vaccination, Hospitalization, mRNA-1273, delta variant, BNT162b2, mRNA, symptomatic, Effectiveness, death, Case-control, Mild, circulation, England, booster dose, Pfizer-BioNTech, AstraZeneca, booster, Moderna, booster vaccination, ChAdOx1-S, Booster vaccine, Evidence, dose, severe disease, evidence of, no evidence of, Messenger RNA, second dose, individual, all age groups, symptomatic disease, dominant, Course, provide, Against, ranged, all age group, Limited, of BNT162b2, offered, 【제목키워드】 COVID-19, Hospitalization, death, Booster vaccine, COVID-19-related symptoms,